Glenmark Pharmaceuticals Overview
- Year Founded
-
1977
- Status
-
Public
- Employees
-
11,719
- Stock Symbol
-
532296
- Investments
-
9
- Share Price
-
$9.70
- (As of Wednesday Closing)
Glenmark Pharmaceuticals General Information
Description
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.
Contact Information
- Glenmark House, B. D. Sawant Marg
- Chakala Off Western Express Highway, Andheri (E)
- Mumbai, Maharashtra 400099
- India
Glenmark Pharmaceuticals Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.70 | $9.33 | $4.53 - $10.58 | $2.74B | 282M | 57.1K | -$0.04 |
Glenmark Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2023 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 |
|---|---|---|---|---|
| EV | 3,328,585 | 1,990,963 | 2,008,334 | 2,045,144 |
| Revenue | 1,561,941 | 1,584,779 | 1,633,955 | 1,452,425 |
| EBITDA | 126,655 | 224,979 | 297,503 | 292,540 |
| Net Income | (10,663) | 37,018 | 126,391 | 130,382 |
| Total Assets | 2,404,386 | 2,359,493 | 2,252,891 | 2,124,502 |
| Total Debt | 622,744 | 563,603 | 522,499 | 678,829 |
Glenmark Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Glenmark Pharmaceuticals Comparisons
Industry
Financing
Details
000000
000000
Glenmark Pharmaceuticals Competitors (34)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Strides Pharma Science | Corporation | Bangalore, India | 0000 | 000.00 | 000000000 | 000.00 |
| 0000000 000000 | Formerly PE-Backed | New Delhi, India | 00000 | 00000 | 00000000 | 00000 |
| 00000000 00000 | Corporation | Mumbai, India | 00 | 00.000 | 00000000000 | 00.000 |
| 00000000 00000000 | Corporation | Noida, India | 0000 | 00000 | 00000000000 | 00000 |
| 00000 | Corporation | Mumbai, India | 00000 | 0&0 |
Glenmark Pharmaceuticals Patents
Glenmark Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220257878-A1 | Metered dose inhalers of fluticasone or an ester thereof | Pending | 15-Feb-2021 | 000000000 | |
| US-20210196631-A1 | Container system and pharmaceutical foam composition comprising betamethasone | Pending | 28-Aug-2018 | 000000000 | 0 |
| US-D914095-S1 | Label | Active | 16-May-2018 | 00 | |
| CA-3078783-A1 | Topical pharmaceutical composition of adapalene and minocycline | Inactive | 24-Oct-2017 | 000000000 | |
| EP-3700504-A4 | Topical pharmaceutical composition of adapalene and minocycline | Inactive | 24-Oct-2017 | A61P17/10 | 0 |
Glenmark Pharmaceuticals Executive Team (20)
Glenmark Pharmaceuticals Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| 0000000 00000 00.0 | Self | Board Member | 000 0000 |
| 0000000 00000000 | Self | Board Member | 000 0000 |
| 00000 0000000 00.0 | Self | Board Member | 000 0000 |
| 000000000 00000 | Glenmark Pharmaceuticals | Executive Director of Corporate Services and Executive Member | 000 0000 |
| 0.0. 00000 | Glenmark Pharmaceuticals | Board Member & Independent Director | 000 0000 |
Glenmark Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Glenmark Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Glenmark Pharmaceuticals Investments & Acquisitions (9)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Sintesy | 26-Apr-2023 | 0000000000 | Other Commercial Products | ||
| Wockhardt (OTC drugs) | 28-Jun-2022 | 000000000 | Buildings and Property | ||
| IndoHealth Services | 30-Apr-2021 | 000000000 | 00.000 | Other Healthcare Services | |
| Zorg Laboratories | 16-Jul-2018 | 0000000000 | Distributors/Wholesale | ||
| Medicamenta | 26-Mar-2007 | Merger/Acquisition | Drug Discovery |
Glenmark Pharmaceuticals Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Glenmark Life Sciences | Pharmaceuticals | Solapur, India | 2011 |
| Sintesy | Other Commercial Products | Milan, Italy | 0000 |
Glenmark Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated February, 03, 2023
32.42 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,708
Rank
Percentile
Pharmaceuticals
Industry
00 of 884
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 418
Rank
Percentile
Glenmark Pharmaceuticals Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Napo Pharmaceuticals | 22-Dec-2005 | 00000 00000 00 | 00.000 | Completed |
|